In the medical community, the treatment of recalcitrant cancers has always been a challenge. However, with the emergence of proteomics methods, a whole new kind of prospect is being unveiled. Antonio I**Arone, M.D., professor of neurosurgery at the University of Miami Miller School of Medicine and associate director of the Sylvester Comprehensive Cancer Center, noted that the introduction of proteomics has opened up new avenues for patients whose tumor cells look similar to healthy neurons.
In a recent study published in the journal Cancer Cell, scientists used proteomics methods for the first time to explore the transition from admissibility to refractory glioblastoma. Through molecular analysis, researchers are able to identify the major kinases in different tumor stages and select the appropriate drugs for laboratory testing based on the activity of these kinases. In a study of BRAF (B-RAF proto-oncogene) kinase, scientists found that a BRAF inhibitor (vemurafenib) used in combination with chemotherapy significantly extended the survival time of mice containing human tumor organoids.
For patients with GBM, a clinical trial is under discussion that will evaluate the efficacy of BRAF inhibitors in patients with neuronal states. In addition, researchers are exploring other BRAF inhibitors to ensure that the most effective inhibitors are selected to prevent the transition of drug resistance in tumors.
Proteomics not only provides new protocols, but also brings new hope to cancer research. In the past, the evolutionary trajectory of tumors was almost a mystery, but now, the application of proteomics has led to a deeper understanding of individual tumors. By collecting large amounts of data and analyzing the proteome and protein modifications, scientists are able to uncover important changes that were previously undetected, improving accuracy.
Despite some challenges, such as cost and access to data, the application of proteomics holds great promise for cancer**. With the continuous development of related technologies and methods, it is believed that in the near future, we will be able to better deal with recalcitrant cancers and bring better outcomes to patients.
These groundbreaking discoveries will not only change our understanding of cancer, but will also provide clinicians with more effective options. The University of Miami's Translational Cancer Research Building, which is under construction, will be one of the important platforms for these scientific discoveries to be translated into clinical applications.